Literature DB >> 7297411

Aversive effects of naltrexone in subjects not dependent on opiates.

L E Hollister, K Johnson, D Boukhabza, H K Gillespie.   

Abstract

Naltrexone was given to ten opiate-free volunteer subjects following the same dosage schedule used for initiating treatment of opiate-dependent persons. During the three-week initiation period, three subjects dropped from the study owing to aversive effects of the drug. The remaining seven subjects reported similar unpleasant but tolerable effects. A separate group of ten volunteer subjects was given single doses of 50 or 100 mg of naltrexone or a naltrexone placebo on three separate occasions using blind controls. These subjects also reported aversive effects. The principal symptoms reported were loss of energy, gastrointestinal disturbances and mental depression. It is possible that these aversive reactions of naltrexone have limited acceptance of the drug as a treatment for opiate-dependent persons.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7297411     DOI: 10.1016/0376-8716(81)90084-3

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  27 in total

1.  Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement.

Authors:  James R Shoblock; Natalie Welty; Leah Aluisio; Ian Fraser; S Timothy Motley; Kirsten Morton; James Palmer; Pascal Bonaventure; Nicholas I Carruthers; Timothy W Lovenberg; Jamin Boggs; Ruggero Galici
Journal:  Psychopharmacology (Berl)       Date:  2010-12-22       Impact factor: 4.530

2.  Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin.

Authors:  Maria A Sullivan; Suzanne K Vosburg; Sandra D Comer
Journal:  Psychopharmacology (Berl)       Date:  2006-09-14       Impact factor: 4.530

3.  Combining naltrexone and prazosin in a single oral medication decreases alcohol drinking more effectively than does either drug alone.

Authors:  Janice C Froehlich; Brett J Hausauer; Dennis D Rasmussen
Journal:  Alcohol Clin Exp Res       Date:  2013-07-22       Impact factor: 3.455

Review 4.  Neuroendocrine circuits governing energy balance and stress regulation: functional overlap and therapeutic implications.

Authors:  Yvonne M Ulrich-Lai; Karen K Ryan
Journal:  Cell Metab       Date:  2014-03-13       Impact factor: 27.287

5.  Alterations of naltrexone-induced conditioned place avoidance by pre-exposure to high fructose corn syrup or heroin in Sprague-Dawley rats.

Authors:  Stephen Daniels; Paul Marshall; Francesco Leri
Journal:  Psychopharmacology (Berl)       Date:  2015-10-30       Impact factor: 4.530

6.  Depot naltrexone: long-lasting antagonism of the effects of heroin in humans.

Authors:  Sandra D Comer; Eric D Collins; Herbert D Kleber; Elie S Nuwayser; James H Kerrigan; Marian W Fischman
Journal:  Psychopharmacology (Berl)       Date:  2001-11-01       Impact factor: 4.530

7.  Combining Varenicline (Chantix) with Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in a Rodent Model of Alcoholism.

Authors:  Janice C Froehlich; Stephen M Fischer; Julian E Dilley; Emily R Nicholson; Teal N Smith; Nick J Filosa; Logan C Rademacher
Journal:  Alcohol Clin Exp Res       Date:  2016-07-29       Impact factor: 3.455

8.  Cabergoline decreases alcohol drinking and seeking behaviors via glial cell line-derived neurotrophic factor.

Authors:  Sebastien Carnicella; Somayeh Ahmadiantehrani; Dao-Yao He; Carsten K Nielsen; Selena E Bartlett; Patricia H Janak; Dorit Ron
Journal:  Biol Psychiatry       Date:  2009-02-20       Impact factor: 13.382

9.  Separate and combined impact of acute naltrexone and alprazolam on subjective and physiological effects of oral d-amphetamine in stimulant users.

Authors:  Katherine R Marks; Joshua A Lile; William W Stoops; Craig R Rush
Journal:  Psychopharmacology (Berl)       Date:  2014-01-25       Impact factor: 4.530

10.  NIH 11082 produces anti-depressant-like activity in the mouse tail-suspension test through a delta-opioid receptor mechanism of action.

Authors:  Pattipati S Naidu; Aron H Lichtman; Carey C Archer; Everett L May; Louis S Harris; Mario D Aceto
Journal:  Eur J Pharmacol       Date:  2007-03-30       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.